Natural killer cell-based cancer immunotherapy: from basics to clinical trials

被引:10
作者
Shi, Yinghong [1 ,2 ]
Hao, Donglin [1 ]
Qian, Hui [1 ,2 ]
Tao, Zhimin [1 ,2 ,3 ]
机构
[1] Jiangsu Univ, Wujin Hosp, Wujin Inst Mol Diagnost & Precis Canc Med, Changzhou 213017, Jiangsu, Peoples R China
[2] Jiangsu Univ, Sch Med, Jiangsu Prov Key Lab Med Sci & Lab Med, Zhenjiang 212013, Jiangsu, Peoples R China
[3] Jiangsu Univ, Dept Emergency Med, Affiliated Hosp, Zhenjiang 212001, Jiangsu, Peoples R China
基金
中国国家自然科学基金;
关键词
Natural killer cells; Immunotherapy; Tumor microenvironment; Chimeric antigen receptor; Clinical trial; INNATE LYMPHOID-CELLS; GAMMA RECEPTOR-III; REGULATORY T-CELLS; RESIDENT NK CELLS; IN-VIVO EXPANSION; CAR NK-92 CELLS; ANTITUMOR-ACTIVITY; SOLID TUMORS; PHASE-I; EXTRACELLULAR VESICLES;
D O I
10.1186/s40164-024-00561-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Cellular immunotherapy exploits the capacity of the human immune system in self-protection and surveillance to achieve the anti-tumor effects. Natural killer (NK) cells are lymphocytes of innate immune system and they display a unique inherent ability to identify and eliminate tumor cells. In this review, we first introduce the basic characteristics of NK cells in the physiological and pathological milieus, followed by a discussion of their effector function and immunosuppression in the tumor microenvironment. Clinical strategies and reports regarding NK cellular therapy are analyzed in the context of tumor treatment, especially against solid tumors. Given the widely studied T-cell therapy in the recent years, particularly the chimeric antigen receptor (CAR) T-cell therapy, we compare the technical features of NK- and T-cell based tumor therapies at the clinical front. Finally, the technical challenges and potential solutions for both T and NK cell-based immunotherapies in treating tumor malignancies are delineated. By overviewing its clinical applications, we envision the NK-cell based immunotherapy as an up-and-comer in cancer therapeutics.
引用
收藏
页数:26
相关论文
共 214 条
[1]   Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study [J].
Abramson, Jeremy S. ;
Palomba, M. Lia ;
Gordon, Leo I. ;
Lunning, Matthew A. ;
Wang, Michael ;
Arnason, Jon ;
Mehta, Amitkumar ;
Purev, Enkhtsetseg ;
Maloney, David G. ;
Andreadis, Charalambos ;
Sehgal, Alison ;
Solomon, Scott R. ;
Ghosh, Nilanjan ;
Albertson, Tina M. ;
Garcia, Jacob ;
Kostic, Ana ;
Mallaney, Mary ;
Ogasawara, Ken ;
Newhall, Kathryn ;
Kim, Yeonhee ;
Li, Daniel ;
Siddiqi, Tanya .
LANCET, 2020, 396 (10254) :839-852
[2]   Actin Cytoskeleton Remodeling Drives Breast Cancer Cell Escape from Natural Killer-Mediated Cytotoxicity [J].
Al Absi, Antoun ;
Wurzer, Hannah ;
Guerin, Coralie ;
Hoffmann, Celine ;
Moreau, Flora ;
Mao, Xianqing ;
Brown-Clay, Joshua ;
Petrolli, Remi ;
Casellas, Carla Pou ;
Dieterle, Monika ;
Thiery, Jean-Paul ;
Chouaib, Salem ;
Berchem, Guy ;
Janji, Bassam ;
Thomas, Clement .
CANCER RESEARCH, 2018, 78 (19) :5631-5643
[3]   Pilot trial of the hu14.18-IL2 immunocytokine in patients with completely resectable recurrent stage III or stage IV melanoma [J].
Albertini, Mark R. ;
Yang, Richard K. ;
Ranheim, Erik A. ;
Hank, Jacquelyn A. ;
Zuleger, Cindy L. ;
Weber, Sharon ;
Neuman, Heather ;
Hartig, Greg ;
Weigel, Tracey ;
Mahvi, David ;
Henry, Mary Beth ;
Quale, Renae ;
McFarland, Thomas ;
Gan, Jacek ;
Carmichael, Lakeesha ;
Kim, KyungMann ;
Loibner, Hans ;
Gillies, Stephen D. ;
Sondel, Paul M. .
CANCER IMMUNOLOGY IMMUNOTHERAPY, 2018, 67 (10) :1647-1658
[4]   IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype [J].
Alizadeh, Darya ;
Wong, Robyn A. ;
Yang, Xin ;
Wang, Dongrui ;
Pecoraro, Joseph R. ;
Kuo, Cheng-Fu ;
Aguilar, Brenda ;
Qi, Yue ;
Ann, David K. ;
Starr, Renate ;
Urak, Ryan ;
Wang, Xiuli ;
Forman, Stephen J. ;
Brown, Christine E. .
CANCER IMMUNOLOGY RESEARCH, 2019, 7 (05) :759-772
[5]   Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells [J].
Andre, Pascale ;
Denis, Caroline ;
Soulas, Caroline ;
Bourbon-Caillet, Clarisse ;
Lopez, Julie ;
Arnoux, Thomas ;
Blery, Mathieu ;
Bonnafous, Cecile ;
Gauthier, Laurent ;
Morel, Ariane ;
Rossi, Benjamin ;
Remark, Romain ;
Breso, Violette ;
Bonnet, Elodie ;
Habif, Guillaume ;
Guia, Sophie ;
Lalanne, Ana Ines ;
Hoffmann, Caroline ;
Lantz, Olivier ;
Fayette, Jerome ;
Boyer-Chammard, Agnes ;
Zerbib, Robert ;
Dodion, Pierre ;
Ghadially, Hormas ;
Jure-Kunkel, Maria ;
Morel, Yannis ;
Herbst, Ronald ;
Narni-Mancinelli, Emilie ;
Cohen, Roger B. ;
Vivier, Eric .
CELL, 2018, 175 (07) :1731-+
[6]   Natural Killer Cell Subsets in Tumor Draining Lymph Nodes of Patients with Bladder Cancer and Their Clinical Implications [J].
Ariafar, Ali ;
Kohansal, Erfan ;
Mousania, Amirhassan ;
Faghih, Zahra .
IRANIAN JOURNAL OF IMMUNOLOGY, 2024, 21 (02) :121-131
[7]   A Phase I Study of Locoregional High-Dose Autologous Natural Killer Cell Therapy With Hepatic Arterial Infusion Chemotherapy in Patients With Locally Advanced Hepatocellular Carcinoma [J].
Bae, Woo Kyun ;
Lee, Byung Chan ;
Kim, Hyeon-Jong ;
Lee, Je-Jung ;
Chung, Ik-Joo ;
Cho, Sung Bum ;
Koh, Yang Seok .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[8]   Granzyme B degradation by autophagy decreases tumor cell susceptibility to natural killer-mediated lysis under hypoxia [J].
Baginska, Joanna ;
Viry, Elodie ;
Berchem, Guy ;
Poli, Aurelie ;
Noman, Muhammad Zaeem ;
van Moer, Kris ;
Medves, Sandrine ;
Zimmer, Jacques ;
Oudin, Anais ;
Niclou, Simone P. ;
Bleackley, R. Chris ;
Goping, Ing Swie ;
Chouaib, Salem ;
Janji, Bassam .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2013, 110 (43) :17450-17455
[9]   Immunosuppressive landscape in hepatocellular carcinoma revealed by single-cell sequencing [J].
Bai, Yi ;
Chen, Dapeng ;
Cheng, Chuanliang ;
Li, Zhongmin ;
Chi, Hao ;
Zhang, Yuliang ;
Zhang, Xiaoyu ;
Tang, Shaohai ;
Zhao, Qiang ;
Ang, Bing ;
Zhang, Yamin .
FRONTIERS IN IMMUNOLOGY, 2022, 13
[10]   First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors [J].
Bang, Y. J. ;
Giaccone, G. ;
Im, S. A. ;
Oh, D. Y. ;
Bauer, T. M. ;
Nordstrom, J. L. ;
Li, H. ;
Chichili, G. R. ;
Moore, P. A. ;
Hong, S. ;
Stewart, S. J. ;
Baughman, J. E. ;
Lechleider, R. J. ;
Burris, H. A. .
ANNALS OF ONCOLOGY, 2017, 28 (04) :855-861